Kindred Biosciences announces Herbert Montgomery to its Board of Directors

– USA, CA – Kindred Biosciences, Inc. (KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Mr. Herbert Montgomery will be joining the Company’s Board of Directors. Mr. Montgomery will serve as the Chairman of the Company’s Audit Committee.

Mr. Montgomery has extensive experience in finance, including having served as CFO of several public companies, and having taken three companies public. Most recently, he was Vice Chairman of the Board and Executive Officer of Lightpost Holdings, LLC. Prior to that, Mr. Montgomery was Executive Vice President, Chief Financial Officer, and Treasurer of Standard Media International; Senior Vice President, Chief Financial Officer and Treasurer of Cotelligent, Inc.; and Senior Vice President, Chief Financial Officer and Treasurer of Guy F. Atkinson. He holds a Master of Science degree in Management and a Bachelor of Science degree in Finance from California State University, Northridge. Mr. Montgomery was also previously Chairman of the Board of Institute for OneWorld Health.

“We are very pleased to welcome Herbert Montgomery to our Board of Directors,” stated Richard Chin, CEO of KindredBio. “I had the pleasure of serving with Herb previously and know, firsthand, the value he will bring to KindredBio.”

Mr. Montgomery stated, “I am delighted to be a part of the highly talented team of professionals who are developing innovative medications that will make a difference in our pets’ quality of life.”

About Kindred Biosciences, Inc.

Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats, and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here the original post =>